Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595412 | 0.78 | NPC1 (0.41) | CTSVCTSLMRGPRX4NPC1HPGD | |
| SCHEMBL20562834 | 0.73 | CHRNA7 (0.46) | CTSVCTSLTDP1KMT2ANPC1 | |
| SCHEMBL8548569 | 0.71 | ACP3 (0.36) | TDP1 | |
| SCHEMBL17833744 | 0.71 | CHRNA7 (0.47) | CTSVCTSLTDP1KMT2ANPC1 | |
| SCHEMBL8324406 | 0.69 | KMO (0.33) | KMT2ANPC1 | |
| SCHEMBL7369416 | 0.69 | SCD (0.52) | CTSVCTSLMRGPRX4KMT2ANPC1 | |
| SCHEMBL9027404 | 0.69 | P2RX7 (0.31) | — | |
| SCHEMBL2462343 | 0.67 | KMT2A (0.53) | KMT2ANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL8035471 | 0.67 | CTSV (0.54) | CTSVCTSLMRGPRX4NPC1HPGD | |
| SCHEMBL17833747 | 0.66 | CHRNA7 (0.46) | CTSVCTSLKMT2ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296952-B9 | BENZOYLPYRIDINE DERIVATIVE OR ITS SALT, FUNGICIDE CONTAINING IT AS AN ACTIVE INGREDIENT, ITS PRODUCTION PROCESS AND INTERMEDIATE FOR PRODUCING IT | ISHIHARA SANGYO KAISHA (JP) | 2008-01-09 | — | — | EP | disclosed |
| EP-1296952-B1 | BENZOYLPYRIDINE DERIVATIVE OR ITS SALT, FUNGICIDE CONTAINING IT AS AN ACTIVE INGREDIENT, ITS PRODUCTION PROCESS AND INTERMEDIATE FOR PRODUCING IT | ISHIHARA SANGYO KAISHA (JP) | 2007-09-12 | — | — | EP | disclosed |
| US-6770662-B2 | PLANT DISEASES; POWDERY MILDEW OF BARLEY, VEGETABLES, FRUITS AND FLOWERING PLANTS | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20030216444-A1 | Benzoylpyridine derivative or its salt, fungicide containing it as an active ingredient, its production process and intermediate for producing it | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216444-A1 | Benzoylpyridine derivative or its salt, fungicide containing it as an active ingredient, its production process and intermediate for producing it | CBR1, KCNH1, CBR3 | CTSV 4369/4885CTSL 2985/4885TDP1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.